952 related articles for article (PubMed ID: 29222911)
41. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.
Bazerbachi F; Vargas EJ; Rizk M; Maselli DB; Mounajjed T; Venkatesh SK; Watt KD; Port JD; Basu R; Acosta A; Hanouneh I; Gara N; Shah M; Mundi M; Clark M; Grothe K; Storm AC; Levy MJ; Abu Dayyeh BK
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):146-154.e4. PubMed ID: 32360804
[TBL] [Abstract][Full Text] [Related]
42. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
[TBL] [Abstract][Full Text] [Related]
43. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
Younossi ZM; Reyes MJ; Mishra A; Mehta R; Henry L
Aliment Pharmacol Ther; 2014 Jan; 39(1):3-14. PubMed ID: 24206433
[TBL] [Abstract][Full Text] [Related]
44. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
45. Nonalcoholic Fatty Liver Disease and Obesity Treatment.
Brunner KT; Henneberg CJ; Wilechansky RM; Long MT
Curr Obes Rep; 2019 Sep; 8(3):220-228. PubMed ID: 30945129
[TBL] [Abstract][Full Text] [Related]
46. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
[TBL] [Abstract][Full Text] [Related]
47. Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered.
Plaz Torres MC; Aghemo A; Lleo A; Bodini G; Furnari M; Marabotto E; Miele L; Giannini EG
Nutrients; 2019 Dec; 11(12):. PubMed ID: 31817398
[TBL] [Abstract][Full Text] [Related]
48. Clinical Trial Landscape in NASH.
Harrison SA; Loomba R; Dubourg J; Ratziu V; Noureddin M
Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2001-2014. PubMed ID: 37059159
[TBL] [Abstract][Full Text] [Related]
49. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
50. Review article: the management of paediatric nonalcoholic fatty liver disease.
Mitchel EB; Lavine JE
Aliment Pharmacol Ther; 2014 Nov; 40(10):1155-70. PubMed ID: 25267322
[TBL] [Abstract][Full Text] [Related]
51. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
52. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
53. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
[TBL] [Abstract][Full Text] [Related]
54. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
Carr RM; Oranu A; Khungar V
Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
[TBL] [Abstract][Full Text] [Related]
55. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
Crespo M; Lappe S; Feldstein AE; Alkhouri N
Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
[TBL] [Abstract][Full Text] [Related]
56. Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology.
Takahashi Y; Fukusato T
World J Gastroenterol; 2010 Nov; 16(42):5280-5. PubMed ID: 21072890
[TBL] [Abstract][Full Text] [Related]
57. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
58. Current Options and Future Directions for NAFLD and NASH Treatment.
Zhang C; Yang M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299189
[TBL] [Abstract][Full Text] [Related]
59. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Harrison SA; Ratziu V; Anstee QM; Noureddin M; Sanyal AJ; Schattenberg JM; Bedossa P; Bashir MR; Schneider D; Taub R; Bansal M; Kowdley KV; Younossi ZM; Loomba R
Aliment Pharmacol Ther; 2024 Jan; 59(1):51-63. PubMed ID: 37786277
[TBL] [Abstract][Full Text] [Related]
60. Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH).
Puengel T; Tacke F
Expert Opin Investig Drugs; 2023; 32(6):451-461. PubMed ID: 37376813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
